Sandoz

FDA approves first biosimilar Zarxio from Sandoz

Friday, March 6, 2015 12:24 PM

Sandoz, a Novartis company, has became the first company to receive approval of a biosimilar in the U.S. through the new FDA biosimilar pathway established under the Biologics Price Competition and Innovation Act.

More... »

Quest Diagnostics

3SBio acquires Sirton Pharmaceuticals

Monday, January 26, 2015 02:25 PM

3SBio, a China-based biotechnology company, has acquired the entire share capital of Sirton Pharmaceuticals, located in Villa Guardia, Italy, from First Shanghai, a financial services provider.

More... »


As GSK restructuring cuts 900 jobs in RTP, Parexel absorbs 450 of them in new business unit

Monday, December 8, 2014 01:30 PM

GlaxoSmithKline’s global restructuring was felt sharply in North Carolina this week as it announced plans to cut 900 jobs in Research Triangle Park (RTP), where it has 2,500 employees and contractors working in research and development.

More... »

UCB to sell generics business to private equity firms Advent, Avista Capital for $1.525 billion

Monday, November 10, 2014 12:26 PM

Advent International and Avista Capital Partners, two private equity firms with a strong healthcare focus, have agreed to acquire UCB’s U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals (KU). UCB is a multinational biopharmaceutical manufacturing company headquartered in Brussels, Belgium.

More... »

Report: Biosimilars could create $44B in healthcare savings

Wednesday, November 5, 2014 12:52 PM

Introducing competing biosimilar versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the U.S. by $44 billion over the next decade, according to a new analysis from RAND, a Boston, Mass.-based nonprofit research organization that develops solutions to public policy challenges.

More... »

Cinven to invest in Medpace

Monday, February 24, 2014 12:40 PM

European private equity firm Cinven has announced a majority investment in Medpace, for $915 million plus certain cash inflows relating to the period of ownership, acquired from CCMP Capital Advisors.

More... »

PTC Therapeutics appoints Zeldis to board of directors

Thursday, October 4, 2012 12:14 PM

PTC Therapeutics, a biopharmaceutical company based in South Plainfield, N.J., has appointed Jerome B. Zeldis, M.D., Ph.D., to the company's board of directors.

More... »

DART Therapeutics appoints executive team

Friday, September 14, 2012 01:51 PM

DART Therapeutics, a Cambridge, Mass.-based new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), has appointed an executive team. Members include co-founder and executive chairman Eugene W. Williams with the new title of CEO, Ernest D. Bush, PhD, as chief scientific officer., Dr. Elliot Goldstein as chief medical officer, and Cabot Brown as chief financial officer.

More... »

Novartis to acquire Fougera Pharmaceuticals

Friday, May 4, 2012 08:02 AM

Switzerland-based Novartis has signed a definitive agreement to acquire specialty dermatology generics company Fougera Pharmaceuticals of Melville, N.Y., for $1.5 billion in cash.

More... »

CRO top executives in a game of ‘musical chairs’

Monday, November 7, 2011 08:02 AM

Five months after INC Research’s acquisition of Kendle International closed, executives from the now-combined CRO are landing jobs with competitors.  

More... »


CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs